These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21277747)

  • 1. Distributed lags time series analysis versus linear correlation analysis (Pearson's r) in identifying the relationship between antipseudomonal antibiotic consumption and the susceptibility of Pseudomonas aeruginosa isolates in a single Intensive Care Unit of a tertiary hospital.
    Erdeljić V; Francetić I; Bošnjak Z; Budimir A; Kalenić S; Bielen L; Makar-Aušperger K; Likić R
    Int J Antimicrob Agents; 2011 May; 37(5):467-71. PubMed ID: 21277747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M; Carbonnelle S; Avrain L; Mesaros N; Pirnay JP; Bilocq F; De Vos D; Simon A; Piérard D; Jacobs F; Dediste A; Tulkens PM; Van Bambeke F; Glupczynski Y
    Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics].
    Alişkan H; Colakoğlu S; Turunç T; Demiroğlu YZ; Erdoğan F; Akin S; Arslan H
    Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of antibiotic resistance patterns of Pseudomonas aeruginosa and Acinetobacter spp. strains isolated from intensive care patients between 2000-2002 and 2003-2006 periods in Dokuz Eylul University Hospital, Izmir].
    Yüce A; Yapar N; Eren Kutsoylu O
    Mikrobiyol Bul; 2009 Apr; 43(2):195-202. PubMed ID: 19621603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).
    Mutnick AH; Rhomberg PR; Sader HS; Jones RN
    J Antimicrob Chemother; 2004 Feb; 53(2):290-6. PubMed ID: 14711839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
    Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R
    Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pseudomonas aeruginosa: antimicrobial resistance in clinical isolates. Castellón 2004-2008].
    Pardo Serrano FJ; Tirado Balaguer MD; García Zúñiga ED; Granados Ortega J; Campos Aznar A; Moreno Muñoz R
    Rev Esp Quimioter; 2010 Mar; 23(1):20-6. PubMed ID: 20232020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased resistance of Pseudomonas aeruginosa with restriction of ciprofloxacin in a large teaching hospital's intensive care and intermediate care units.
    Lewis GJ; Fang X; Gooch M; Cook PP
    Infect Control Hosp Epidemiol; 2012 Apr; 33(4):368-73. PubMed ID: 22418632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
    Eagye KJ; Banevicius MA; Nicolau DP
    Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment.
    Philippe E; Weiss M; Shultz JM; Yeomans F; Ehrenkranz NJ
    Clin Perform Qual Health Care; 1999; 7(2):83-7. PubMed ID: 10747571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensive care antibiotic consumption and resistance patterns: a cross-correlation analysis.
    Baditoiu L; Axente C; Lungeanu D; Muntean D; Horhat F; Moldovan R; Hogea E; Bedreag O; Sandesc D; Licker M
    Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):71. PubMed ID: 29132352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India.
    Goel N; Wattal C; Oberoi JK; Raveendran R; Datta S; Prasad KJ
    J Antimicrob Chemother; 2011 Jul; 66(7):1625-30. PubMed ID: 21586594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
    López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
    Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
    Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
    Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002.
    Mohr JF; Jones A; Ostrosky-Zeichner L; Wanger A; Tillotson G
    Int J Antimicrob Agents; 2004 Oct; 24(4):346-51. PubMed ID: 15380259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.
    Chin JN; Jones RN; Sader HS; Savage PB; Rybak MJ
    J Antimicrob Chemother; 2008 Feb; 61(2):365-70. PubMed ID: 18079128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility pattern of clinical isolates of Pseudomonas aeruginosa.
    Al-Jasser AM; Elkhizzi NA
    Saudi Med J; 2004 Jun; 25(6):780-4. PubMed ID: 15195211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.